SP
ABBV icon

Sequent Planning’s AbbVie ABBV Stock Holding History

Sequent Planning’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Sell
1,325
-2
-0.2% -$430 0.07% 198
2026
Q1 		$289K Sell
1,327
-131
-9% -$29.1K 0.07% 189
2025
Q4 		$333K Buy
1,458
+147
+11% +$33.5K 0.08% 162
2025
Q3 		$303K Buy
1,311
+9
+0.7% +$1.83K 0.09% 164
2025
Q2 		$242K Buy
1,302
+229
+21% +$42.6K 0.08% 141
2025
Q1 		$225K Buy
+1,073
New +$209K 0.08% 133

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sequent Planning's ABBV Position: Q2 2026 in Review

Sequent Planning reduced its AbbVie (ABBV) stake by 0.15% in Q2 2026, selling an estimated $430 and leaving 1,325 shares worth $333K. The position accounts for 0.07% of the portfolio, ranked #198.

Sequent Planning first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sequent Planning held 1,325 shares of AbbVie worth $333K as of Q2 2026.
  • Sequent Planning sold 2 AbbVie shares in Q2 2026, an estimated $430.
  • AbbVie made up 0.07% of Sequent Planning's portfolio in Q2 2026, its #198 holding.
  • Sequent Planning first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sequent Planning's 13F filing for Q2 2026, filed 14 Aug 2026.